watch
Seattle Genetics, Inc.

Seattle Genetics, Inc.

Sector: Pharmaceutical Preparations Region: WA, United States


: | Nasdaq: SGEN


Similar to: Mast Therapeutics, Inc., Transgene SA, United-Guardian, Inc.

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product ADCETRIS or brentuximab vedotin has been approved by both U.S. Food and Drug Association and Health Canada in U.S. and Canada respectively. ADCETRIS is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E. The company was founded by Clay B. Siegall and H. Perry Fell in 1998 and is headquartered in Bothell, WA.

News & Analysis

You may also be interested in: